Loading...
Loading...
BioNexus Gene Lab Corp
BioNexus Gene Lab Corp. Spoken Alpha tracks BGLC's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks BGLC's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters but stock falls 80% of the time
SampleWhen a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for BGLC.
curl https://api.spokenalpha.com/v1/companies/BGLC| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $3.60 | $2.52 | +42.8% | -0.5% | +1.2% |
| Q4 FY2026 | $3.58 | $2.38 | +50.3% | -3.7% | -6.1% |
| Q3 FY2026 | $3.66 | $2.62 | +39.8% | -4.4% | -5.3% |
| Q2 FY2026 | $3.96 | $2.68 | +47.6% | -4.0% | -5.7% |
| Q1 FY2025 | $3.67 | $2.66 | +38.0% | -4.5% | -1.9% |
| Q4 FY2025 | $3.76 | $2.53 | +48.6% | +1.8% | +1.1% |
| Q3 FY2025 | $3.78 | $2.74 | +37.9% | -5.1% | -4.8% |
| Q2 FY2025 | $3.92 | $2.74 | +42.9% | -5.9% | -6.6% |
| Q1 FY2024 | $3.55 | $2.57 | +38.3% | -0.3% | -2.9% |
| Q4 FY2024 | $4.23 | $2.81 | +50.6% | +4.4% | +7.3% |